^
    3years
    A Study of HS269 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, Zhejiang Hisun Pharmaceutical Co. Ltd.
    Clinical • New P1 trial
    |
    RET (Ret Proto-Oncogene)
    |
    RET mutation
    |
    HS269